FPA144

DRUG3 trials

Sponsors

Five Prime Therapeutics, Inc., Amgen

Conditions

Advanced Solid TumorsGastric CancerGastric or Gastroesophageal CancerRecurrent Bladder CancerTransitional Cell Carcinoma of the Bladder

Phase 1

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

CompletedNCT02318329

Five Prime Therapeutics, Inc.Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder

Start: 2014-11-30End: 2019-06-30Updated: 2024-06-04

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

CompletedNCT05913115

AmgenGastric or Gastroesophageal Cancer

Start: 2017-06-12End: 2018-06-19Updated: 2023-06-22

Unknown Phase

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Five Prime Therapeutics, Inc.Recurrent Bladder Cancer

Updated: 2021-12-13

Related Papers

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial

Cancer Chemotherapy and Pharmacology2020-09-236 citations

Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design

Future Oncology2019-05-1667 citations

Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.

Journal of Clinical Oncology2017-05-2011 citations

Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model

Cancer Research2016-07-157 citations

Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.

Journal of Clinical Oncology2016-05-207 citations

FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.

Journal of Clinical Oncology2016-02-0111 citations